Clinical Trial Update: Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating whether intravenous ferric carboxymaltose improves mortality, cardiovascular morbidity, and quality of life in iron-deficient …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Deficiency Anemia
• Myocardial Infarction

Drugs mentioned

• Ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: Wroclaw Medical University | Conditions: Myocardial Infarction, Acute | Phase 4 | Status: RECRUITING